Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 10:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 4,807 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sensitivity Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

NeoMatriX Wound Matrix Collagen Dressing Skin Prick Test

NCT03522675
View directory record Official record
Conditions
Allergy Skin, Allergy, Dermatitis, Allergic Contact
Interventions
NeoMatriX Wound MatriX Collagen Dressing
Device
Lead sponsor
NeXtGen Biologics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Not applicable Interventional Results available

Breathe With Ease: A Unique Approach to Managing Stress (BEAMS)

NCT02374138
View directory record Official record
Conditions
Asthma
Interventions
Parental stress management, Usual Care
Behavioral · Other
Lead sponsor
Stephen J. Teach, MD, MPH
Other
Eligibility
4 Years to 12 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Oct 27, 2026, 10:38 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Development of a Breath Analyzer for Asthma Screening

NCT00386737
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Ekips Technologies
Industry
Eligibility
4 Years to 65 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Norman, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 12, 2006 · Synced Oct 27, 2026, 10:38 PM EDT
Completed No phase listed Observational

A Novel Method to Determine HIV Incidence Among Youth

NCT00103883
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 24 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
14
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 27, 2026, 10:38 PM EDT
Terminated No phase listed Observational Results available

Protein Biomarker Discovery and Validation in Chronic Obstructive Pulmonary Disease (COPD) And Asthma

NCT02487394
View directory record Official record
Conditions
Asthma, COPD
Interventions
Exhaled Breath Condensate (EBC)
Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 27, 2026, 10:38 PM EDT
Terminated Phase 2 Interventional

A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

NCT06881251
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, JNJ-95475939, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
13
States / cities
Fountain Valley, California • Los Angeles, California • Alpharetta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Phase 2 Interventional

Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis

NCT05432596
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ATI-1777 2.0% w/w, ATI-1777 1.0% w/w, ATI-1777 0.5% w/w, Vehicle
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
32
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bryant, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Phase 2 Interventional Results available

Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis

NCT04598269
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ATI-1777, Vehicle
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
14
States / cities
Scottsdale, Arizona • Encino, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluating Peanut Immunotherapy Dissolving Film in Healthy Subjects

NCT03070561
View directory record Official record
Conditions
Peanut Allergy, Immunotherapy, Pharmacokinetics
Interventions
sublingual film with peanut extract
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
3 Years to 30 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Phase 4 Interventional

A Multi-Center Study of Short and Long-term Use of Protopic Ointment in Patients With Atopic Dermatitis

NCT00106496
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Protopic, Corticosteroid, placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
2 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
24
States / cities
Birmingham, Alabama • Irvine, California • Loma Linda, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of Viaskin Peanut to Treat Peanut Allergy

NCT02916446
View directory record Official record
Conditions
Peanut Allergy
Interventions
Viaskin Peanut 250 µg, Placebo
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
4 Years to 11 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
26
States / cities
Little Rock, Arkansas • Mission Viejo, California • Rolling Hills Estates, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Not applicable Interventional Results available

HIRREM Developmental Study

NCT02709369
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders, Anxiety, Post-Traumatic Stress Disorder, Hot Flashes, Headache, Traumatic Brain Injury, Post Concussion Symptoms
Interventions
HIRREM
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
11 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 24, 2019 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma

NCT02040766
View directory record Official record
Conditions
Asthma
Interventions
Beclomethasone dipropionate BAI, Placebo BAI, albuterol/salbutamol 90 mcg, Beclomethasone dipropionate MDI, Placebo MDI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
75
States / cities
Hoover, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 27, 2026, 10:38 PM EDT
Terminated Phase 1 Interventional

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

NCT05733351
View directory record Official record
Conditions
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone, Biospecimen Collection, Bone Scan, Computed Tomography, Docetaxel, Enzalutamide, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, PSMA PET Scan, Vudalimab
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 27, 2026, 10:38 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)

NCT00389103
View directory record Official record
Conditions
Smallpox, Atopic Dermatitis
Interventions
MVA (smallpox vaccine)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
3
States / cities
Albuquerque, New Mexico • Portland, Oregon • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Oct 27, 2026, 10:38 PM EDT
Terminated Phase 2 Interventional Results available

Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer

NCT03649841
View directory record Official record
Conditions
Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Antiandrogen Therapy, Abiraterone Acetate, Prednisone, Radiation Therapy
Drug · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Not applicable Interventional

CHARGE: Controlling Hunger and ReGulating Eating

NCT03678766
View directory record Official record
Conditions
Binge-Eating Disorder, Overweight, Obesity
Interventions
Regulation of Cues (ROC), Cognitive Behavior Therapy (CBT)
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 27, 2026, 10:38 PM EDT
Enrolling by invitation Phase 2 Interventional

Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma

NCT06609239
View directory record Official record
Conditions
Asthma
Interventions
Lunsekimig
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
31
States / cities
Chandler, Arizona • Tucson, Arizona • Aurora, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes

NCT00605475
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Canakinumab, Placebo, Metformin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
6
States / cities
Little Rock, Arkansas • Miami, Florida • MD, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Oct 27, 2026, 10:38 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Effects of Hesperidin on Insulin Sensitivity

NCT01773486
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Hesperidin, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 27, 2026, 10:38 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

NCT02612454
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
6 Months to 17 Years
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
40
States / cities
Birmingham, Alabama • Gilbert, Arizona • Bakersfield, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Phase 1 Interventional Results available

AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis

NCT04897594
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
TERN-201, Placebo
Drug · Other
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
11
States / cities
Tucson, Arizona • Coronado, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 27, 2026, 10:38 PM EDT
Active, not recruiting No phase listed Observational

A Study to Learn About the Outcomes Between Study Medicines, Enzalutamide and Darolutamide Among Men With Metastatic Castration Sensitive Prostate Cancer (mCSPC)

NCT07779590
View directory record Official record
Conditions
Metastatic Castration Sensitive Prostate Cancer (mCSPC)
Interventions
darolutamide plus androgen deprivation therapy, Enzalutamide plus androgen deprivation therapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
4,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 27, 2026, 10:38 PM EDT
Completed Phase 2 Interventional

Effect of Medical Food on Reducing Asthma Symptoms in Asthmatic Children

NCT01087710
View directory record Official record
Conditions
Asthma
Interventions
medical food with EPA and GLA, vitamins and minerals, medical food minus EPA and GLA, antioxidant vitamins/minerals
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
6 Years to 14 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 16, 2010 · Synced Oct 27, 2026, 10:38 PM EDT